Treatment of acromegaly in the era of personalized and predictive medicine

Clinical Endocrinology

Volumn 83, Issue 1, 2015, Pages 3-14

  Puig Domingo, Manuel ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; AROMATIC HYDROCARBON; BETA ARRESTIN 1; BIOLOGICAL MARKER; CABERGOLINE; DOPAMINE RECEPTOR; GROWTH HORMONE; HYPOPHYSIS HORMONE; KI 67 ANTIGEN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEW DRUG; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; PROTEIN P27; RAF PROTEIN; SOMATOSTATIN RECEPTOR; UVOMORULIN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ARYL HYDROCARBON RECEPTOR-INTERACTING PROTEIN; BETA ARRESTIN; CADHERIN; CYCLOPEPTIDE; G PROTEIN COUPLED RECEPTOR; RETINA S ANTIGEN; SIGNAL PEPTIDE; SOMATOSTATIN;

ACROMEGALY; ARTICLE; CANCER RADIOTHERAPY; COMORBIDITY; DECISION MAKING; DISEASE CONTROL; DRUG EFFICACY; ENZYME ACTIVITY; FAMILIAL ISOLATED PITUITARY ADENOMA; GENE EXPRESSION; GERMLINE MUTATION; GROWTH HORMONE SECRETING ADENOMA; HIGH OUTPUT HEART FAILURE; HUMAN; HYPOPHYSIS ADENOMA; LONG TERM CARE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOSURGERY; SLEEP DISORDERED BREATHING; SURGICAL APPROACH; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR VOLUME; ADENOMA; ALGORITHM; ANALOGS AND DERIVATIVES; GENETICS; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; METABOLISM; MUTATION; NEUROSURGERY; PATHOLOGY; TREATMENT OUTCOME;

ADENOMA; ALGORITHMS; ANTINEOPLASTIC AGENTS, HORMONAL; ARRESTINS; CADHERINS; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KI-67 ANTIGEN; MUTATION; NEUROSURGICAL PROCEDURES; OCTREOTIDE; PEPTIDES, CYCLIC; PRECISION MEDICINE; PROGNOSIS; RAF KINASES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84932195962     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12731     Document Type: Article

References (98)

1. Ezzat, S., Asa, S.L., Couldwell, W.T., et al,. (2004) The prevalence of pituitary adenomas: a systematic review. Cancer, 101, 613-619.
2. Daly, A.F., Rixhon, M., Adam, C., et al,. (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. Journal of Clinical Endocrinology and Metabolism, 91, 4769-4775.
3. Sesmilo, G., (2013) Epidemiology of acromegaly in Spain. Endocrinología y Nutriciõn, 60, 470-474.
4. Mestron, A., Webb, S.M., Astorga, R., et al,. (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). European Journal of Endocrinology, 151, 439-446.
5. Luque-Ramirez, M., Carreno, A., Alvarez Escola, C., et al,. (2011) The OASIS study: therapeutic management of acromegaly in standard clinical practice. Assessment of the efficacy of various treatment strategies. Endocrinología y Nutriciõn, 58, 478-486.
6. Dekkers, O.M., Biermasz, N.R., Pereira, A.M., et al,. (2008) Mortality in acromegaly: a metaanalysis. Journal of Clinical Endocrinology and Metabolism, 93, 61-67.
7. Holdaway, I.M., Bolland, M.J., &, Gamble, G.D., (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. European Journal of Endocrinology, 159, 89-95.
8. Katznelson, L., Atkinson, J.L., Cook, D.M., et al,. (2011) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update. Endocrine Practice, 17 (Suppl 4), 1-44.
9. Manjila, S., Wu, O.C., Khan, F.R., et al,. (2010) Pharmacological management of acromegaly: a current perspective. Neurosurgical Focus, 29, E14.
10. Melmed, S., Colao, A., Barkan, A., et al,. (2009) Guidelines for acromegaly management: an update. Journal of Clinical Endocrinology and Metabolism, 94, 1509-1517.
11. Giustina, A., Chanson, P., Kleinberg, D., et al,. (2014) Expert consensus document: a consensus on the medical treatment of acromegaly. Nature Reviews. Endocrinology, 10, 243-248.
12. Colao, A., Auriemma, R.S., Lombardi, G., et al,. (2011) Resistance to somatostatin analogs in acromegaly. Endocrine Reviews, 32, 247-271.
13. Melmed, S., (1990) Acromegaly. New England Journal of Medicine, 322, 966-977.
14. Katznelson, L., Laws, E.R. Jr, Melmed, S., et al,. (2014) Acromegaly: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 99, 3933-3951.
15. Spada, A., Arosio, M., Bochicchio, D., et al,. (1990) Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. Journal of Clinical Endocrinology and Metabolism, 71, 1421-1426.
16. Diamond, L., O'Brien, T.G., &, Baird, W.M., (1980) Tumor promoters and the mechanism of tumor promotion. Advances in Cancer Research, 32, 1-74.
17. Melmed, S., Braunstein, G.D., Horvath, E., et al,. (1983) Pathophysiology of acromegaly. Endocrine Reviews, 4, 271-290.
18. Melmed, S., (2009) Acromegaly pathogenesis and treatment. The Journal of Clinical Investigation, 119, 3189-3202.
19. Biller, B.M., Colao, A., Petersenn, S., et al,. (2010) Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocrine Disorders, 10, 10.
20. Fougner, S.L., Bollerslev, J., Svartberg, J., et al,. (2014) Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial. European Journal of Endocrinology, 171, 229-235.
21. Shen, M., Shou, X., Wang, Y., et al,. (2010) Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocrine Journal, 57, 1035-1044.
22. Colao, A., Ferone, D., Cappabianca, P., et al,. (1997) Effect of octreotide pretreatment on surgical outcome in acromegaly. Journal of Clinical Endocrinology and Metabolism, 82, 3308-3314.
23. Ayuk, J., Stewart, S.E., Stewart, P.M., et al,. (2004) Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clinical Endocrinology, 60, 375-381.
24. Losa, M., Mortini, P., Urbaz, L., et al,. (2006) Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. Journal of Neurosurgery, 104, 899-906.
25. Beckers, A., (2008) Does preoperative somatostatin analog treatment improve surgical cure rates in acromegaly? A new look at an old question. Journal of Clinical Endocrinology and Metabolism, 93, 2975-2977.
26. Burton, T., Le Nestour, E., Bancroft, T., et al,. (2013) Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases. Pituitary, 16, 354-362.
27. Wang, Y.Y., Higham, C., Kearney, T., et al,. (2012) Acromegaly surgery in Manchester revisited-the impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission. Clinical Endocrinology (Oxford), 76, 399-406.
28. Colao, A., Attanasio, R., Pivonello, R., et al,. (2006) Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism, 91, 85-92.
29. Hardy, J., (1969) Transphenoidal microsurgery of the normal and pathological pituitary. Clinical Neurosurgery, 16, 185-217.
30. Bhayana, S., Booth, G.L., Asa, S.L., et al,. (2005) The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. Journal of Clinical Endocrinology and Metabolism, 90, 6290-6295.
31. Jallad, R.S., Musolino, N.R., Kodaira, S., et al,. (2007) Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clinical Endocrinology, 67, 310-315.
32. Karavitaki, N., Turner, H.E., Adams, C.B., et al,. (2008) Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clinical Endocrinology, 68, 970-975.
33. Freda, P.U., Katznelson, L., van der Lely, A.J., et al,. (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism, 90, 4465-4473.
34. Ghigo, E., Biller, B.M., Colao, A., et al,. (2009) Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy. Journal of Endocrinological Investigation, 32, 924-933.
35. Maiza, J.C., Vezzosi, D., Matta, M., et al,. (2007) Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clinical Endocrinology, 67, 282-289.
36. Weckbecker, G., Lewis, I., Albert, R., et al,. (2003) Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nature Reviews. Drug Discovery, 2, 999-1017.
37. Duran-Prado, M., Saveanu, A., Luque, R.M., et al,. (2010) A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. Journal of Clinical Endocrinology and Metabolism, 95, 2497-2502.
38. Zatelli, M.C., Piccin, D., Ambrosio, M.R., et al,. (2006) Antiproliferative effects of somatostatin analogs in pituitary adenomas. Pituitary, 9, 27-34.
39. Luque, R.M., Sanchez-Tejada, L., Ibañez-Costa, A., et al,. (2013) OR26-1 REMAH: The Spanish Molecular Registry of Pituitary Adenomas. A Clinical-molecular Multicenter Research Network to Study Pituitary Adenomas: Initial Data on the Molecular Profile of GH-producing Adenomas. ENDO, San Francisco, CA, USA.
40. Ferone, D., de Herder, W.W., Pivonello, R., et al,. (2008) Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. Journal of Clinical Endocrinology and Metabolism, 93, 1412-1417.
41. Taboada, G.F., Luque, R.M., Neto, L.V., et al,. (2008) Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. European Journal of Endocrinology, 158, 295-303.
42. Plockinger, U., Albrecht, S., Mawrin, C., et al,. (2008) Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. Journal of Clinical Endocrinology and Metabolism, 93, 1203-1210.
43. Casar-Borota, O., Heck, A., Schulz, S., et al,. (2013) Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide. Journal of Clinical Endocrinology and Metabolism, 98, E1730-E1739.
44. Gatto, F., Feelders, R., van der Pas, R., et al,. (2013) beta-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly. Endocrinology, 154, 4715-4725.
45. Fougner, S.L., Lekva, T., Borota, O.C., et al,. (2010) The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. Journal of Clinical Endocrinology and Metabolism, 95, 2334-2342.
46. Florio, T., (2008) Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Frontiers in Bioscience, 13, 822-840.
47. Ballare, E., Persani, L., Lania, A.G., et al,. (2001) Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. Journal of Clinical Endocrinology and Metabolism, 86, 3809-3814.
48. Puig-Domingo, M., Luque, R.M., Reverter, J.L., et al,. (2014) The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer. PLoS ONE, 9, e85527.
49. Baragli, A., Alturaihi, H., Watt, H.L., et al,. (2007) Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cellular Signalling, 19, 2304-2316.
50. Rocheville, M., Lange, D.C., Kumar, U., et al,. (2000) Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science, 288, 154-157.
51. Zatelli, M.C., Piccin, D., Tagliati, F., et al,. (2005) Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro. Journal of Molecular Endocrinology, 35, 333-341.
52. Neto, L.V., Machado Ede, O., Luque, R.M., et al,. (2009) Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. Journal of Clinical Endocrinology and Metabolism, 99, E2789-E2793.
53. Chahal, H.S., Trivellin, G., Leontiou, C.A., et al,. (2012) Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. Journal of Clinical Endocrinology and Metabolism, 97, E1411-E1420.
54. Schöfl, C., Honegger, J., Droste, M., et al,. (2014) Frequency of AIP gene mutations in young patients with acromegaly: a registry-based study. Journal of Clinical Endocrinology and Metabolism, 99, E2789-E2793.
55. Oriola, J., Lucas, T., Halperin, I., et al,. (2013) Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues. European Journal of Endocrinology, 168, 9-13.
56. Kasuki, L., Vieira Neto, L., Wildemberg, L.E., et al,. (2012) AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocrine-Related Cancer, 19, L25-L29.
57. Fougner, S.L., Bollerslev, J., Latif, F., et al,. (2008) Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. Journal of Clinical Endocrinology and Metabolism, 93, 1211-1216.
58. Fu, Z., Smith, P.C., Zhang, L., et al,. (2003) Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. Journal of the National Cancer Institute, 95, 878-889.
59. Barlier, A., Gunz, G., Zamora, A.J., et al,. (1998) Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas. Journal of Clinical Endocrinology and Metabolism, 83, 1604-1610.
60. Kato, M., Inoshita, N., Sugiyama, T., et al,. (2012) Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocrine Journal, 59, 221-228.
61. Lesche, S., Lehmann, D., Nagel, F., et al,. (2009) Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. Journal of Clinical Endocrinology and Metabolism, 94, 654-661.
62. Colao, A., Bronstein, M.D., Freda, P., et al,. (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. Journal of Clinical Endocrinology and Metabolism, 99, 791-799.
63. Gadelha, M.R., Bronstein, M.D., Brue, T., et al,. (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. The Lancet. Diabetes & Endocrinology 2, 875-884.
64. Fleseriu, M., Sheppard, M., Bronstein, M., et al,. (2012) Pasireotide LAR vs octreotide LAR in patients with acromegaly: double-blind, crossover, extension period to a randomized, double-blind, multicenter, phase III study. Endocrine Abstracts, 29, P1404.
65. Neggers, S.J., van Aken, M.O., Janssen, J.A., et al,. (2007) Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. Journal of Clinical Endocrinology and Metabolism, 92, 4598-4601.
66. Marazuela, M., Lucas, T., Alvarez-Escola, C., et al,. (2009) Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. European Journal of Endocrinology, 160, 535-542.
67. Pantel, J., Machinis, K., Sobrier, M.L., et al,. (2000) Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution. Journal of Biological Chemistry, 275, 18664-18669.
68. Dos Santos, C., Essioux, L., Teinturier, C., et al,. (2004) A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nature Genetics, 36, 720-724.
69. Bernabeu, I., Alvarez-Escola, C., Quinteiro, C., et al,. (2010) The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly. Journal of Clinical Endocrinology and Metabolism, 95, 222-229.
70. Filopanti, M., Olgiati, L., Mantovani, G., et al,. (2012) Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. Journal of Clinical Endocrinology and Metabolism, 97, E165-E172.
71. Howlett, T.A., Willis, D., Walker, G., et al,. (2013) Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clinical Endocrinology, 79, 689-699.
72. Lamberts, S.W., Uitterlinden, P., Schuijff, P.C., et al,. (1988) Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical 'cure'. Clinical Endocrinology, 29, 411-420.
73. Lindsay, J.R., McConnell, E.M., Hunter, S.J., et al,. (2004) Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels. Pituitary, 7, 139-144.
74. Pokrajac, A., Claridge, A.G., Shakoor, S.K., et al,. (2006) The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly. European Journal of Endocrinology, 154, 267-274.
75. Halah, F.P., Elias, L.L., Martinelli, C.E. Jr, et al,. (2004) Usefulness of subcutaneous or long-acting octreotide as a predictive test and in the treatment of acromegaly. Arquivos Brasileiros de Endocrinologia e Metabologia, 48, 245-252.
76. Biermasz, N.R., Pereira, A.M., Smit, J.W., et al,. (2005) Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. Growth Hormone & IGF Research, 15, 200-206.
77. Karavitaki, N., Botusan, I., Radian, S., et al,. (2005) The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clinical Endocrinology, 62, 282-288.
78. Gilbert, J.A., Miell, J.P., Chambers, S.M., et al,. (2005) The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly. Clinical Endocrinology, 62, 742-747.
79. Halperin, I., Nicolau, J., Casamitjana, R., et al,. (2008) A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients. Hormone and Metabolic Research, 40, 422-426.
80. Bandgar, T.R., Sarathi, V., Shivane, V., et al,. (2010) The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly. Journal of Postgraduate Medicine, 56, 7-11.
81. Jenkins, P.J., Emery, M., Howling, S.J., et al,. (2004) Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR. Hormone Research, 62, 227-232.
82. Cozzi, R., Attanasio, R., Montini, M., et al,. (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? Journal of Clinical Endocrinology and Metabolism, 88, 3090-3098.
83. Hagiwara, A., Inoue, Y., Wakasa, K., et al,. (2003) Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology, 228, 533-538.
84. Heck, A., Ringstad, G., Fougner, S.L., et al,. (2012) Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clinical Endocrinology, 77, 72-78.
85. Puig-Domingo, M., Resmini, E., Gomez-Anson, B., et al,. (2010) Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. Journal of Clinical Endocrinology and Metabolism, 95, 4973-4978.
86. Higham, C.E., Atkinson, A.B., Aylwin, S., et al,. (2012) Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. Journal of Clinical Endocrinology and Metabolism, 97, 1187-1193.
87. Lee, C.C., Vance, M.L., Xu, Z., et al,. (2014) Stereotactic radiosurgery for acromegaly. Journal of Clinical Endocrinology and Metabolism, 99, 1273-1281.
88. Tuvia, S., Atsmon, J., Teichman, S.L., et al,. (2012) Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. Journal of Clinical Endocrinology and Metabolism, 97, 2362-2369.
89. Chieffo, C., Cook, D., Xiang, Q., et al,. (2013) Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 98, 4047-4054.
90. Plockinger, U., Hoffmann, U., Geese, M., et al,. (2012) DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. European Journal of Endocrinology, 166, 223-234.
91. Vilar, L., Naves, L.A., Costa, S.S., et al,. (2007) Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly. Endocrine Practice, 13, 363-372.
92. Melmed, S., Casanueva, F.F., Klibanski, A., et al,. (2013) A consensus on the diagnosis and treatment of acromegaly complications. Pituitary, 16, 294-302.
93. Broder, M.S., Neary, M.P., Chang, E., et al,. (2014) Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases. Pituitary, 17, 333-341.
94. Vilar, L., Valenzuela, A., Ribeiro-Oliveira, A. Jr, et al,. (2014) Multiple facets in the control of acromegaly. Pituitary, 17 (Suppl 1), S11-S17.
95. Maione, L., Garcia, C., Bouchachi, A., et al,. (2012) No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 97, E1714-E1719.
96. Erem, C., Ersoz, H.O., Ukinc, K., et al,. (2006) Acromegaly presenting with diabetic ketoacidosis, associated with retinitis pigmentosa and octreotide-induced bradycardia: a case report and a review of the literature. Endocrine, 30, 145-149.
97. Mazziotti, G., Floriani, I., Bonadonna, S., et al,. (2009) Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. Journal of Clinical Endocrinology and Metabolism, 94, 1500-1508.
98. Sheppard, M., Bronstein, M.D., Freda, P., et al,. (2014) Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. Pituitary, DOI 10.1007/s11102-014-0585-6